Hansoh Registers Phase 2 Trial of HS-20137 in Plaque Psoriasis
Start here
Hansoh BioMedical R&D Company has registered a Phase 2 open-label clinical trial, NCT07879885, evaluating the safety and efficacy of HS-20137 in participants with moderate-to-severe plaque psoriasis. The study plans to enroll 390 participants and is currently recruiting. HS-20137 is administered as a biologic intervention. The trial's registration marks the public entry of this candidate into mid-stage clinical testing for psoriasis; results on safety and efficacy, and any subsequent development of the program, are still ahead.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- clinicaltrials.govAn Open-label Study of HS-20137 in Participants With Moderate-to-Severe Plaque Psoriasis
Hansoh BioMedical R&D Company has registered NCT07879885, a Phase 2 open-label study evaluating the safety and efficacy of HS-20137 in moderate-to-severe plaque psoriasis. The study plans to enroll 390 participants, is currently recruiting, and the intervention is a biological agent, HS-20137.
Coverage and heat for this story
Reports so far 1·Heat now 5·Peak heat 10 (Oct 19 20:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.